Zobrazeno 1 - 10
of 72
pro vyhledávání: ''
Publikováno v:
Current Medical Research and Opinion. 32:1131-1136
Objective The present study aimed to compare the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin and saxagliptin on 24 hour acute glucose fluctuations in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately control
Publikováno v:
Expert Opinion on Pharmacotherapy. 16:2835-2848
The use of direct-acting antiviral (DAA) agents against chronic hepatitis C virus (HCV) infections can result in the successful treatment of nearly all patients. Effective antiviral treatments can prevent the progression to cirrhosis and hepatocellul
Publikováno v:
Current Medical Research and Opinion. 31:2273-2285
To assess the efficacy of fenofibrate and statin dual therapy versus a double or equivalent dose of statin monotherapy.A systematic literature search and meta-analysis was performed for publications before 1 January 2014 in MEDLINE, Embase, and BIOSI
Publikováno v:
Expert Opinion on Pharmacotherapy. 16:2231-2241
Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action of dopamine in the brain. It has been demonstrated that rasagiline can improve motor and some non-motor symptoms (NMS) in both earl
Autor:
Antonio Riccardo Buonomo, Guglielmo Borgia, Ivan Gentile, Emanuela Zappulo, Alberto Enrico Maraolo
Publikováno v:
Expert Opinion on Investigational Drugs. 24:1111-1121
About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosi
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 11:1157-1165
Introduction: Telaprevir is one of the first direct-acting antiviral drugs approved for the treatment of the hepatitis C virus (HCV) genotype 1. Following its approval in 2011, new data regarding the pharmacokinetics and pharmacodynamics were reporte
Publikováno v:
Expert Opinion on Pharmacotherapy. 16:617-624
INTRODUCTION: Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) has revolutionized the care of infected patients. Among these novel compounds are non-nucleoside analogs, which bind viral RNA- dependent RNA polymerase
Publikováno v:
Current Medical Research and Opinion. 31:85-94
To assess the effect of active vitamin D3 on quality of life (QOL) and pain in raloxifene-treated Japanese women with postmenopausal osteoporosis.This is a post hoc analysis of a previous prospective postmarketing observational study conducted withou
Autor:
Guido Stirnimann
Publikováno v:
Expert Opinion on Pharmacotherapy. 15:2609-2622
Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-actin
Autor:
Rosemarie Lajara
Publikováno v:
Expert Opinion on Pharmacotherapy. 15:2565-2585
Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of glucose-lowering agents developed for the treatment of type 2 diabetes mellitus (T2DM). These agents have a mechanism of action that is independent of pancreatic β-cell function o